Latest Conference Articles

Cutting Daily Sodium Intake Significantly Lowers Blood Pressure in 1 Week, According to New Research

Cutting Daily Sodium Intake Significantly Lowers Blood Pressure in 1 Week, According to New Research

November 15th 2023

American Heart Association

AHA 2023: Reducing daily sodium intake by about 4000 mg significantly lowered SBP in approximately 73% of adults in 1 week when compared to a higher sodium diet.

Systolic BP Target of <120 mm Hg Reduces CV Event Risk, According to New Data from AHA Scientific Sessions 2023

Systolic BP Target of <120 mm Hg Reduces CV Event Risk, According to New Data from AHA Scientific Sessions 2023

November 14th 2023

American Heart Association

AHA 2023: An intensive 3-year treatment targeting SPB <120 mm Hg resulted in 39% lower CV mortality than standard treatment in patients with HTN at high risk of CVD.

Speech May be a Promising Biomarker for MHE, OHE, According to New Research

Speech May be a Promising Biomarker for MHE, OHE, According to New Research

November 13th 2023

AASLD The Liver Meeting 2023

TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.

How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement

How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement

November 13th 2023

AASLD The Liver Meeting 2023

TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.

NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds

NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds

November 12th 2023

AASLD The Liver Meeting 2023

More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.

Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral

Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral

November 11th 2023

AASLD The Liver Meeting 2023

One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.

FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research

FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.

New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries

New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.

New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives

New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

Novel Algorithm, FAST-3,  Shows Promise as Noninvasive Classifier for Advanced Fibrosis  in MASLD

Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD

November 10th 2023

AASLD The Liver Meeting 2023

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.